Kymera Therapeutics Inc
KYMR43.104USD
+0.144+0.34%
Market hours （ET）Quotes delayed by 15 min
2.81BMarket Cap
LossP/E TTM
More Details of Kymera Therapeutics Inc Company
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.
Company Info
Ticker SymbolKYMR
Company nameKymera Therapeutics Inc
IPO dateAug 21, 2020
CEODr. Nello Mainolfi, Ph.D.
Number of employees188
Security typeOrdinary Share
Fiscal year-endAug 21
Address500 North Beacon Street, 4Th Floor
CityWATERTOWN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02472
Phone18572855314
Websitehttps://www.kymeratx.com/
Ticker SymbolKYMR
IPO dateAug 21, 2020
CEODr. Nello Mainolfi, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
67.50K
+23.48%
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Justine Koenigsberg
Ms. Justine Koenigsberg
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bruce N. Jacobs
Mr. Bruce N. Jacobs
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
67.50K
+23.48%
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Justine Koenigsberg
Ms. Justine Koenigsberg
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Revenue Breakdown
FY2024
No Data
By RegionUSD
Name
Revenue
Proportion
United States
47.07M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
9.48%
T. Rowe Price Associates, Inc.
9.48%
Avoro Capital Advisors LLC
9.21%
Wellington Management Company, LLP
8.55%
BVF Partners L.P.
7.81%
Other
55.48%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
9.48%
T. Rowe Price Associates, Inc.
9.48%
Avoro Capital Advisors LLC
9.21%
Wellington Management Company, LLP
8.55%
BVF Partners L.P.
7.81%
Other
55.48%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.90%
Investment Advisor/Hedge Fund
31.55%
Hedge Fund
22.61%
Venture Capital
8.27%
Individual Investor
1.40%
Corporation
1.10%
Research Firm
0.91%
Private Equity
0.41%
Bank and Trust
0.39%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
393
75.73M
107.94%
-273.58K
2025Q1
408
74.79M
106.76%
-4.90M
2024Q4
392
73.17M
112.73%
-3.17M
2024Q3
379
71.17M
110.57%
-5.78M
2024Q2
360
69.86M
113.52%
-7.55M
2024Q1
364
70.22M
115.13%
-982.70K
2023Q4
350
63.05M
113.62%
-5.46M
2023Q3
341
59.94M
108.11%
-9.64M
2023Q2
349
61.24M
110.72%
-7.83M
2023Q1
353
62.67M
113.41%
-6.15M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
6.65M
9.48%
+655.50K
+10.93%
Jun 30, 2025
T. Rowe Price Associates, Inc.
6.65M
9.48%
-169.69K
-2.49%
Mar 31, 2025
Avoro Capital Advisors LLC
6.46M
9.21%
+1.31M
+25.44%
Mar 31, 2025
Wellington Management Company, LLP
6.00M
8.55%
+689.55K
+12.99%
Mar 31, 2025
BVF Partners L.P.
5.48M
7.81%
+317.17K
+6.14%
Jun 30, 2025
The Vanguard Group, Inc.
5.22M
7.45%
+344.08K
+7.05%
Mar 31, 2025
Atlas Venture
4.90M
6.98%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.41M
6.28%
-421.36K
-8.72%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.63M
5.17%
-76.67K
-2.07%
Mar 31, 2025
Invus Public Equities Advisors, LLC
3.24M
4.62%
+270.58K
+9.11%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.83%
Harbor Human Capital Factor US Small Cap ETF
0.7%
SPDR S&P Biotech ETF
0.44%
Invesco Nasdaq Biotechnology ETF
0.32%
ProShares Ultra Nasdaq Biotechnology
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
First Trust Multi-Manager Small Cap Opportunities ETF
0.25%
T Rowe Price Small-Mid Cap ETF
0.24%
iShares Biotechnology ETF
0.24%
iShares Russell 2000 Growth ETF
0.14%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.83%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.7%
SPDR S&P Biotech ETF
Proportion0.44%
Invesco Nasdaq Biotechnology ETF
Proportion0.32%
ProShares Ultra Nasdaq Biotechnology
Proportion0.32%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.25%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.25%
T Rowe Price Small-Mid Cap ETF
Proportion0.24%
iShares Biotechnology ETF
Proportion0.24%
iShares Russell 2000 Growth ETF
Proportion0.14%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
